ARTICLE | Clinical News
Semafore preclinical data
July 26, 2004 7:00 AM UTC
In a mouse model of prostate cancer, SF1126 reduced tumors by 74% in a dose- and frequency-dependent manner (p<0.0005). The PI3 kinase inhibitor also reduced tumor vessel density. Data were presented...